Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.43 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918655 | 0.87 | ANO1 (0.44) | ABCB1ANO1KDM4EMEN1ALDH1A1 | |
| SCHEMBL1918982 | 0.85 | KCNH2 (0.52) | KCNH2CYP2C8 | |
| SCHEMBL253511 | 0.82 | GAA (0.53) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL253936 | 0.79 | KCNH2 (0.47) | KCNH2CYP2C8 | |
| SCHEMBL120304 | 0.76 | RAB9A (0.56) | ANO1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL9948040 | 0.76 | ANO1 (0.42) | ABCB1ANO1KDM4EMEN1ALDH1A1 | |
| SCHEMBL243503 | 0.75 | KCNH2 (0.50) | KCNH2CYP2C8 | |
| SCHEMBL17464346 | 0.74 | KCNH2 (0.53) | KCNH2KDM4EALDH1A1CYP2C8 | |
| SCHEMBL9948375 | 0.72 | MEN1 (0.51) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3631501 | 0.70 | GAA (0.42) | KCNH2ANO1MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096580-B2 | Benzofuran derivatives for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150141395-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-21 | — | — | US | disclosed |
| US-8507683-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120309770-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141395-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | HAVCR2, UGT2B7, GOT1 | ABCB1 81/4885KCNH2 3615/4885ANO1 2887/4885 |
| US-20120309770-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | ABCB1 111/4885KCNH2 3814/4885ANO1 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.